A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
At a glance
- Drugs OP-101 (Primary)
- Indications Adrenoleucodystrophy; Neurological disorders
- Focus Adverse reactions
- Sponsors Orpheris
- 16 Apr 2018 Status changed from planning to recruiting.
- 05 Dec 2017 New trial record
- 27 Nov 2017 According to an Orpheris media release, this trial is anticipated to complete in Q1 2018.